Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cidara Therapeutics (CDTX) stocks in Canada

Learn how to easily invest in Cidara Therapeutics stocks.

Cidara Therapeutics is a biotechnology business based in the US. Cidara Therapeutics stocks (CDTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.83 – an increase of 0.46% over the previous week. Cidara Therapeutics employs 89 staff and has a trailing 12-month revenue of around $49.6 million.

How to buy stocks in Cidara Therapeutics

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CDTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cidara Therapeutics stock price (NASDAQ:CDTX)

Use our graph to track the performance of CDTX stocks over time.

Cidara Therapeutics shares at a glance

Information last updated 2022-05-12.
Latest market close$0.46
52-week range$0.42 - $2.39
50-day moving average $0.78
200-day moving average $1.32
Wall St. target price$6.09
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.81

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cidara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cidara Therapeutics price performance over time

Historical closes compared with the close of $0.4621 from 2022-05-18

1 week (2022-05-12) 0.46%
1 month (2022-04-19) -42.95%
3 months (2022-02-17) -41.30%
6 months (2021-11-19) -69.19%
1 year (2021-05-20) -77.68%
2 years (2020-05-19) -86.37%
3 years (2019-05-17) 2.02
5 years (2017-05-19) 6.8

Cidara Therapeutics financials

Revenue TTM $49.6 million
Gross profit TTM $-23,515,000
Return on assets TTM -38.91%
Return on equity TTM -263.05%
Profit margin -85.67%
Book value $0.32
Market capitalisation $41.1 million

TTM: trailing 12 months

Cidara Therapeutics share dividends

We're not expecting Cidara Therapeutics to pay a dividend over the next 12 months.

Cidara Therapeutics share price volatility

Over the last 12 months, Cidara Therapeutics's shares have ranged in value from as little as $0.4189 up to $2.39. A popular way to gauge a stock's volatility is its "beta".

CDTX.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cidara Therapeutics's is 1.3338. This would suggest that Cidara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cidara Therapeutics overview

Cidara Therapeutics, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site